IFNB1 and myeloid sarcoma: An observational cohort study found a lower risk of conversion to secondary progressive MS in patients initially treated with fingolimod, natalizumab or alemtuzumab, compared to those starting treatment with interferon beta or glatiramer acetate, with a hazard ratio of 0.66 ​at 5 years [157].